Targeted therapy of inflammatory bowel diseases: realities and prospects
This review article was designed to systematize the literature data concerning the role of targeted therapy in the treatment of patients with inflammatory bowel diseases. It presents the data of the latest randomized clinical trials and meta-analyses evaluating the efficacy and safety of targeted drugs for the treatment of Crohn’s disease and ulcerative colitis..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2018 |
|---|---|
| Erschienen: |
2018 |
| Enthalten in: |
Zur Gesamtaufnahme - year:2018 |
|---|---|
| Enthalten in: |
Медицинский совет - (2018), 6, Seite 114-118 |
| Sprache: |
Russisch |
|---|
| Beteiligte Personen: |
I. V. Maev [VerfasserIn] |
|---|
| Links: |
doi.org [kostenfrei] |
|---|
| doi: |
10.21518/2079-701X-2018-6-114-118 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
DOAJ023239573 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | DOAJ023239573 | ||
| 003 | DE-627 | ||
| 005 | 20230505014149.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230226s2018 xx |||||o 00| ||rus c | ||
| 024 | 7 | |a 10.21518/2079-701X-2018-6-114-118 |2 doi | |
| 035 | |a (DE-627)DOAJ023239573 | ||
| 035 | |a (DE-599)DOAJd6328aad305e41adbac1b5282ce5e21f | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a rus | ||
| 100 | 0 | |a I. V. Maev |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Targeted therapy of inflammatory bowel diseases: realities and prospects |
| 264 | 1 | |c 2018 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a This review article was designed to systematize the literature data concerning the role of targeted therapy in the treatment of patients with inflammatory bowel diseases. It presents the data of the latest randomized clinical trials and meta-analyses evaluating the efficacy and safety of targeted drugs for the treatment of Crohn’s disease and ulcerative colitis. | ||
| 650 | 4 | |a inflammatory bowel disease | |
| 650 | 4 | |a crohn’s disease | |
| 650 | 4 | |a ulcerative colitis | |
| 650 | 4 | |a targeted therapy | |
| 650 | 4 | |a biological therapy | |
| 650 | 4 | |a infliximab | |
| 650 | 4 | |a adalimumab | |
| 650 | 4 | |a golimumab | |
| 650 | 4 | |a cetrolizumab | |
| 650 | 4 | |a tofacinib | |
| 650 | 4 | |a filgotinib | |
| 650 | 4 | |a ustkinumab | |
| 650 | 4 | |a natalizumab | |
| 650 | 4 | |a vedolizumab | |
| 653 | 0 | |a Medicine | |
| 653 | 0 | |a R | |
| 700 | 0 | |a D. N. Andreev |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i In |t Медицинский совет |d Remedium Group LLC, 2019 |g (2018), 6, Seite 114-118 |w (DE-627)DOAJ000029483 |x 26585790 |7 nnns |
| 773 | 1 | 8 | |g year:2018 |g number:6 |g pages:114-118 |
| 856 | 4 | 0 | |u https://doi.org/10.21518/2079-701X-2018-6-114-118 |z kostenfrei |
| 856 | 4 | 0 | |u https://doaj.org/article/d6328aad305e41adbac1b5282ce5e21f |z kostenfrei |
| 856 | 4 | 0 | |u https://www.med-sovet.pro/jour/article/view/2383 |z kostenfrei |
| 856 | 4 | 2 | |u https://doaj.org/toc/2079-701X |y Journal toc |z kostenfrei |
| 856 | 4 | 2 | |u https://doaj.org/toc/2658-5790 |y Journal toc |z kostenfrei |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_DOAJ | ||
| 951 | |a AR | ||
| 952 | |j 2018 |e 6 |h 114-118 | ||